معرفی
Mandar Aras, MD, PhD, is an Associate Professor of Medicine in the School of Medicine at the University of California, San Francisco (UCSF). He serves as an advanced heart failure and heart transplant cardiologist with expertise in managing heart failure, pulmonary hypertension, heart transplants, and mechanical circulatory support devices. He is co-Director of the UCSF Comprehensive Amyloidosis Program and clinical cardiology lead for the UCSF HHT Center of Excellence. His research focuses on infiltrative and inflammatory heart diseases, particularly amyloidosis and immune checkpoint inhibitor cardiotoxicity. He also specializes in cardio-oncology, addressing cardiovascular complications in cancer patients.
Education:
- MD, PhD in Medicine and Neurobiology, University of Pittsburgh (2011)
- Internal Medicine Residency, Duke University Medical Center (2014)
- Cardiovascular Disease Fellowship, UCSF (2017)
- Advanced Heart Failure/Transplant Fellowship, UCSF (2018)
- Diversity, Equity, and Inclusion Champion Training, UCSF (2020)
Research Interests: His work emphasizes understanding mechanisms and therapies for cardiac amyloidosis, immune checkpoint inhibitor-induced cardiotoxicity, and pulmonary hypertension. He also investigates novel diagnostic tools, such as machine learning for echocardiographic analysis and biomarker-driven approaches for early disease detection.
Publications Trends: Dr. Aras' recent articles highlight advancements in amyloidosis treatment (e.g., acoramidis trials), immune checkpoint inhibitor-associated myocarditis, and the cardiovascular impact of Long COVID. His work bridges clinical care and translational research, particularly in high-risk patient populations like cancer survivors and HIV-positive individuals.
Awards:
- ACC Clinical Excellence in Cardiology Fellowship Award (2016)
- Califf Medicine Resident Research Award (2014)
- International Society for Zinc Biology Best Poster (2009) and Student Oral Presentation (2008) Awards
Advising & Grants: While no formal trainees are listed, his clinical trials and collaborative studies (e.g., Cardiac Amyloidosis Registry Study) reflect mentorship in translational and clinical research. His funding focuses on cardiac amyloidosis mechanisms and cardio-oncology.
Labs/Teams: He leads the UCSF Comprehensive Amyloidosis Program and collaborates with the HHT Center of Excellence, emphasizing multidisciplinary care for complex cardiovascular conditions.
